Age-related Macular Deg neration Ranibizumab in Treatment for Age-related Macular Degeneration

Ranibizumab is an antibody fragment (Fab) that binds and inhibits all isoforms of vascular endothelial growth factor (VEGF), which is considered the main target in neovascular age-related macular degeneration (naMd). Based on scientific evidence of the anti-VEGF antibody for the Treatment of Predominantly classic choroidal Neovascularization in aMd (aNchoR)/Minimally classic/occult Trial of the anti-VEGF antibody Ranibizumab in the Treatment of Neovascular aMd (MaRiNa) studies, intravitreal ranibizumab is indicated in all typical types of naMd. Nevertheless, specific forms such as retinal angiomatous proliferation (RaP), polypoidal choroidal vasculopathy (PcV) and bad or non-responders may need combination therapies to increase the efficacy and reduce the number of injections. due to the frequent office visits and injections required with a monthly ranibizumab therapy, several dosing strategies have been evaluated to maintain optimal efficacy while reducing the number of injections and visits in the clinical practice. Pro re nata (PRN) and ‘Treat and Extend’ are the most popular individualised therapeutic regimens. Few studies address long-term results of ranibizumab. it remains controversial whether initial good results can be maintained over time. aMd is a chronic disease and a significant proportion of patients require continued treatment.